The ASPEN Study and reduction of cardiovascular events in patients with diabetes
- PMID: 17169245
The ASPEN Study and reduction of cardiovascular events in patients with diabetes
Comment on
-
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).Diabetes Care. 2006 Jul;29(7):1478-85. doi: 10.2337/dc05-2415. Diabetes Care. 2006. PMID: 16801565 Clinical Trial.